Development of predictive biomarker for kidney transplant disorder by comprehensive structural analysis on serum glycan

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K15579
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Hirosaki University
• Principal Investigator: Ohyama Chikara 弘前大学, 医学研究科, 教授 (80282135)
• Co-Investigator(Kenkyū-buntansha): 畠山 真吾 弘前大学, 医学部附属病院, 講師 (10400136) ; 盛 和行 弘前大学, 医学研究科, 助教 (40266903) ; 米山 徹 弘前大学, 医学研究科, 助教 (50587649) ; 古家 琢也 弘前大学, 医学研究科, 准教授 (60321965) ; 飛澤 悠葵 弘前大学, 医学研究科, 助教 (70623768) ; 佐藤 滋 秋田大学, 医学部, 教授 (80187195)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 腎移植 / 抗体関連拒否 / 糖鎖

Outline of Final Research Achievements

We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 197 LKTx recipients of whom 16 recipients had ABMR with or without T-cell-mediated rejection (TCMR), 40 recipients had TCMR, and 141 recipients had no adverse events. The N-glycan score was calculated by multiplying the level of candidate objective variables by objective function values. The N-glycan score discriminated ABMR with 81.25% sensitivity, 87.85% specificity, and an area under the curve (AUC) of 0.892 that was far superior to that of preformed donor-specific antibody status (AUC, 0.761). Recipients with N-glycan-positive scores >0.8770 had significantly shorter ABMR survival than that of recipients with N-glycan-negative scores.

Free Research Field

泌尿器科学